Photo: Thanasis/Getty Images
Novo Nordisk has announced the launch of its Wegovy pill in the U.S. following FDA approval last month, as well as a collaboration with hybrid weight-inclusive primary and metabolic care provider knownwell.
Knownwell will now be recognized as a NovoCare provider. The Boston-based company has brick-and-mortar locations in Massachusetts, Texas, Illinois and Georgia.
Through the collaboration, patients exploring use of the Wegovy pill will have access to knownwell's offerings that integrate nutritional, medical and behavioral support.
"The availability of Wegovy pill represents an important evolution in obesity care — one that prioritizes convenience, choice, and meeting patients where they are," Brooke Boyarsky Pratt, CEO and cofounder of knownwell, said in a statement.
"We’re excited to be part of this new movement and to support patients who are seeking effective treatment options paired with high-quality, insurance-covered care."
THE LARGER TREND
In November, the White House announced agreements with pharma giants Eli Lilly and Company and Novo Nordisk to offer GLP-1s, including Wegovy, through the prescription digital marketplace TrumpRx.
At the time, the administration said that once Novo Nordisk's Wegovy pill received FDA approval, the initial dose of those medicines will be made available via TrumpRx for $150 per month.
Other Novo Nordisk medications were also be made available via TrumpRx, including commonly used insulin products at $35 per month of supply; NovoLog, a rapid-acting insulin for type 1 and type 2 diabetes; and Tresiba, an ultra-long-acting basal insulin to help control blood sugar in patients with diabetes.
In October, knownwell announced it secured an oversubscribed $25 million in funding, bringing its total raise to more than $50 million.
Earlier in the year, knownwell announced a partnership with Eli Lilly's digital healthcare platform LillyDirect. Knownwell was added to LillyDirect's list of healthcare providers for patients seeking metabolic healthcare.
In 2024, knownwell acquired AI-enabled precision metabolic-health management company Alfie Health, which offered ObesityRx, a platform that analyzes medical histories to determine which treatments will most effectively improve an individual's metabolic health.
Knownwell launched in 2023 with $4.5 million in seed funding and later that year secured $20 million in Series A funding in a round led by Andreessen Horowitz (a16z) Bio + Health.
